Extramedullary disease in multiple myeloma: biology, the potential role of AI, and more
Faith Davies, MBBCh, MRCP, MD, FRCPath, NYU Langone, New York City, NY, and Mehmet Samur, PhD, Dana-Farber Cancer Institute, Boston, MA, discuss the biology of extramedullary disease (EMD) in multiple myeloma. The experts first highlight the differences between paramedullary disease and EMD, and outcomes associated with these. Following this, they touch on the role of imaging and the possibility of using artificial intelligence (AI) in this setting. This discussion took place at the 1st International Workshop on High-Risk Multiple Myeloma (iwHRMM 2024), held in Charleston, SC. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
